Excess Soluble fms-like Tyrosine Kinase 1 Correlates With Endothelial Dysfunction and Organ Failure in Critically Ill Coronavirus Disease 2019 Patients

Vincent Dupont; Lukshe Kanagaratnam; Antoine Goury; Gaël Poitevin; Mathieu Bard; Gauthier Julien; Michel Bonnivard; Vanessa Champenois; Violaine Noel; Bruno Mourvillier; Philippe Nguyen

doi:10.1093/cid/ciaa1007

Excess Soluble fms-like Tyrosine Kinase 1 Correlates With Endothelial Dysfunction and Organ Failure in Critically Ill Coronavirus Disease 2019 Patients

Clin Infect Dis. 2021 May 18;72(10):1834-1837. doi: 10.1093/cid/ciaa1007.

Authors

Affiliations

¹ Medical Intensive Care Unit, University Hospital of Reims, Reims, France.
² EA-3801, SFT CAP-Santé, University of Reims Champagne Ardenne, France.
³ Clinical Research Unit, University Hospital of Reims, Reims, France.
⁴ Department of Internal Medicine, Clinical Immunology and Infectious Diseases, University Hospital of Reims, Reims, France.

Abstract

Excess soluble fms-like tyrosine kinase 1 (sFlt-1), a soluble inhibitor of vascular endothelial growth factor pathway, has been demonstrated to promote endothelial dysfunction. Here, we demonstrate that sFlt-1 plasma levels correlate with respiratory symptom severity, expression of endothelial dysfunction biomarker, and incidence of organ failure in coronavirus disease 2019 patients. Clinical Trials Registration: NCT04394195.

Keywords: COVID-19; critical care; endothelial dysfunction; sFlt-1.

MeSH terms

COVID-19*
Critical Illness
Humans
SARS-CoV-2
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1*

Substances

Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1

Associated data

ClinicalTrials.gov/NCT04394195